Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

29,935 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Orelabrutinib in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma patients: Multi-center, single-arm, open-label, phase 2 study.
Xu W, Zhou K, Wang T, Yang S, Liu L, Hu Y, Zhang W, Ding K, Zhou J, Gao S, Xu B, Zhu Z, Liu T, Zhang H, Hu J, Ji C, Wang S, Xia Z, Wang X, Li Y, Song Y, Ma S, Tang X, Zhang B, Li J. Xu W, et al. Among authors: xu b. Am J Hematol. 2023 Apr;98(4):571-579. doi: 10.1002/ajh.26826. Epub 2023 Jan 22. Am J Hematol. 2023. PMID: 36683422 Free article. Clinical Trial.
[Clonality relatedness and molecular characteristics of Richter transformation].
Sha YQ, Jiang R, Miao Y, Qiu TL, Qin SC, Qiu JY, Mi HL, Wu W, Qiao C, Wu YJ, Xia Y, Wang L, Fan L, Xu W, Li JY, Zhu HY. Sha YQ, et al. Among authors: xu w. Zhonghua Xue Ye Xue Za Zhi. 2022 Oct 14;43(10):841-847. doi: 10.3760/cma.j.issn.0253-2727.2022.10.007. Zhonghua Xue Ye Xue Za Zhi. 2022. PMID: 36709198 Free PMC article. Chinese.
Zanubrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: final results and correlative analysis of lymphocytosis.
Xu W, Yang S, Zhou K, Pan L, Li Z, Gao S, Zhou D, Hu J, Feng R, Huang H, Wang T, Li D, Ji M, Guo H, Zhao X, Wu B, Yu Y, Wang Y, Huang J, Novotny W, Li J. Xu W, et al. Leuk Lymphoma. 2023 Mar;64(3):712-716. doi: 10.1080/10428194.2022.2164692. Epub 2023 Feb 17. Leuk Lymphoma. 2023. PMID: 36799536 No abstract available.
[Efficacy and safety of BTK inhibitor combined with bendamustine and rituximab in the first-line treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma].
Qin SC, Jiang R, Sha YQ, Qiu JY, Mi HL, Miao Y, Wu W, Wang L, Fan L, Xu W, Li JY, Zhu HY. Qin SC, et al. Among authors: xu w. Zhonghua Xue Ye Xue Za Zhi. 2023 Feb 14;44(2):158-161. doi: 10.3760/cma.j.issn.0253-2727.2023.02.014. Zhonghua Xue Ye Xue Za Zhi. 2023. PMID: 36948873 Free PMC article. Chinese. No abstract available.
Orelabrutinib for the treatment of relapsed or refractory MCL: a phase 1/2, open-label, multicenter, single-arm study.
Deng LJ, Zhou KS, Liu LH, Zhang MZ, Li ZM, Ji CY, Xu W, Liu T, Xu B, Wang X, Gao SJ, Zhang HL, Hu Y, Li Y, Cheng Y, Yang HY, Cao JN, Zhu ZM, Hu JD, Zhang W, Jing HM, Ding KY, Zhang XY, Zhao RB, Zhang B, Tian YM, Song YP, Song YQ, Zhu J. Deng LJ, et al. Among authors: xu b, xu w. Blood Adv. 2023 Aug 22;7(16):4349-4357. doi: 10.1182/bloodadvances.2022009168. Blood Adv. 2023. PMID: 37078706 Free PMC article. Clinical Trial.
29,935 results
You have reached the last available page of results. Please see the User Guide for more information.